The Endpoints 11: biopharma’s most promising startups in 2026
True innovation has never been harder to see.
New financial models are changing how and where new drugs get developed. Promising molecules draw a dozen copycats right out the gate. The genuinely risky, boundary-pushing work often happens behind closed doors.
Endpoints editors sifted through the muddle to uncover eleven companies whose work clears the bar. These are the groups building the tools and making the scientific advances that help the industry take leaps forward.
Endpoints 11 is more than a list. It’s a night where founders, investors and the editors who follow them come together in one room.
The Endpoints 11 virtual experience
Watch the highlights from the gala’s fireside chat and editorial introductions, then go deeper with winner interviews and conversations with the Endpoints editors behind the selections. Free to register.
Agenda to be announced.
The virtual day brings you inside the story: winner interviews, bonus content, and conversations with the Endpoints editors who selected this year’s cohort.
Want to be in the room for the unveiling? Reserve your spot for the in-person gala dinner.
The gala is in-person only, and intentionally intimate. Held at the iconic State Room in Boston, it’s where you’ll hear from the 11 companies first, then spend the evening in conversation with the founders building them, the investors backing them and the journalists who chose them.
Hosted by:
